San Diego-dependent Viking Therapeutics marked alone as a serious competitor while in the weight loss drug marketplace in February immediately after revealing promising details from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection and in March th… Read More